**iRhythm Technologies, Inc. Reports Fiscal Year 2025 Results**
iRhythm Technologies, Inc. (IRTC) has released its financial results for the fiscal year 2025, revealing a net loss of $44.6 million. This marks a significant improvement compared to the $113.3 million net loss reported in the previous fiscal year, 2024. The company's revenue reached $747.1 million, a 26% increase from the $591.8 million recorded in 2024. This growth was primarily driven by increased demand for iRhythm Services, particularly from larger healthcare enterprise accounts utilizing both Zio monitor and Zio AT systems. However, this revenue growth was partially offset by higher contractual allowance reserves due to increased payer claim denials.
The company's cost of revenue also increased, reaching $219.9 million, a 19% rise from the $184.3 million reported in 2024. This increase was attributed to higher headcount, component costs, amortization costs related to Zio monitor and Zio AT printed circuit board assemblies (PCBAs), material scrap costs, and freight expenses. Research and development expenses also saw an increase, climbing to $84.6 million, an 18% increase from the $71.5 million in 2024. This rise was primarily due to higher employee-related costs, product development consulting costs, and costs associated with ongoing FDA remediation and sustaining activities. Selling, general, and administrative expenses increased to $492.6 million, an 18% increase from the $418.6 million in 2024, primarily due to increases in headcount-related costs, legal and professional fees, provisions for credit losses, and claims processing fees.
Strategic developments during the year included the ongoing integration of artificial intelligence (AI) into iRhythm's products and services, including the Zio AT system. The company also continued to pursue international expansion opportunities, particularly in the United Kingdom, selected European countries, and Japan. In August 2024, iRhythm entered into a Technology License Agreement with BioIntelliSense, Inc., granting iRhythm exclusive rights to develop and commercialize certain technologies for remote cardiac monitoring. In June 2025, BioIntelliSense achieved the first of two regulatory milestones under the agreement.
As of December 31, 2025, iRhythm Technologies employed approximately 2,400 full-time employees. The company's cash and cash equivalents totaled $236.0 million, with marketable securities valued at $347.8 million. iRhythm's management believes that its current financial resources, combined with anticipated revenue, will be sufficient to meet its liquidity requirements for at least the next twelve months. The company is focused on expanding access to care, improving clinical outcomes, and informing future growth opportunities, while remaining aligned with its disciplined approach to investment, commercialization, and regulatory compliance.
About iRhythm Technologies, Inc.
iRhythm Technologies Inc. specializes in digital healthcare solutions for cardiac arrhythmia detection through device-based ambulatory monitoring. Its core products include the Zio System, a wire-free, patch-based ECG monitor, and related services that enable long-term, high-accuracy heart rhythm analysis. Serving healthcare providers globally, the company leverages proprietary AI, clinical data, and regulatory expertise to improve diagnosis, reduce costs, and support proactive patient management.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.